Fox Chase Cancer Center News

PHILADELPHIA (December 7, 2022)—Racial disparities in head and neck cancer (HNC) survival are well documented, with Black patients experiencing twice the mortality rate of whites. Previous research has shown that demographic factors like socioeconomic status and access to healthcare play a role. A study published today by researchers at Fox Chase Cancer Center suggests that independent of these factors, race itself may predict disparate outcomes between patients.

PHILADELPHIA (December 7, 2022)—Swayam Prabha, MBA, PhD, a member of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, was recently awarded a $792,000 American Cancer Society research scholar grant to investigate new methods for treating lung cancer.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center’s Stephanie H. Greco, MD, FACS, an assistant professor in the Department of Surgical Oncology and director of Surgical Quality, was recently inducted as a fellow into the Philadelphia Academy of Surgery.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center physicians Hossein Borghaei, DO, MS, and Elizabeth Plimack, MD, MS, have been named to the 2022 list of Highly Cited Researchers by Clarivate, an information and analytics firm focused on research.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center’s Richard J. Bleicher, MD, FACS, a professor in the Department of Surgical Oncology and leader of the Breast Cancer Program, was recently inducted as a fellow into the Philadelphia Academy of Surgery.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center’s Allison A. Aggon, DO, FACOS, an associate professor in the Department of Surgical Oncology, was recently inducted as a fellow into the Philadelphia Academy of Surgery.

PHILADELPHIA (November 18, 2022)—Genetically targeted therapy can make treatment for lung cancer much more effective, but testing to identify specific gene fusions involved in the disease remains a challenge. However, a new study by researchers at Fox Chase Cancer Center demonstrates that RNA next-generation sequencing (RNA-NGS) can offer results that are more accurate and comprehensive while using smaller tissue samples.

PHILADELPHIA (November 17, 2022)—Fox Chase Cancer Center and Oryzon Genomics S.A. will work together to test the safety and efficacy of the drug iadademstat in patients with pulmonary and extrapulmonary neuroendocrine carcinomas (NECs), which are rare and heterogeneous cancers arising from neuroendocrine cells, and small cell lung cancer (SCLC).